UC Irvine

UC Irvine Previously Published Works

Title

PROGRESSION OF CORONARY CALCIUM AND ALL-CAUSE MORTALITY IN PERSONS WITH END STAGE RENAL DISEASE

Permalink

https://escholarship.org/uc/item/6sm2p7zd

Journal

Journal of the American College of Cardiology, 77(18)

ISSN

0735-1097

Authors

Arasheben, Audelia Kinninger, April Dahal, Suraj et al.

Publication Date

2021-05-01

DOI

10.1016/s0735-1097(21)02676-0

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at https://creativecommons.org/licenses/by/4.0/

Peer reviewed





PROGRESSION OF CORONARY CALCIUM AND ALL-CAUSE MORTALITY IN PERSONS WITH END STAGE RENAL DISEASE

Poster Contributions Saturday, May 15, 2021, 9:45 a.m.-10:30 a.m.

Session Title: Multimodality Imaging: CT 1
Abstract Category: 26. Multimodality Imaging: CT

Authors: <u>Audelia Arasheben</u>, April Kinninger, Suraj Dahal, Suvasini Lakshmanan, Ahmed Ghanem, Vahid Rezvanizadeh, Khadije Ahmad, Kamyar Kalantar-Zadeh, Connie Rhee, Elani Streja, Amy You, Geoffrey Cho, Ronald Karlsberg, Matthew Budoff, Lundquist Insitute at Harbor-UCLA, Torrance, CA, USA, University of California, Irvine, Irvine, CA, USA

Background: Previous studies show predictive values of coronary artery calcium (CAC) progression on all-cause mortality in the general population. However, there is limited information on the impact of CAC progression in end stage renal disease (ESRD) patients.

Methods: We evaluated 146 ESRD subjects who had underwent 2 clinically indicated non-contrast gated CT scans of the heart [CAC scan] to measure CAC progression, CAC was then annualized for analysis. Subjects were followed until death, or last confirmed provider visit as censoring date. Time to death/censoring were evaluated by Kaplan Meyer analysis stratified by CAC progression. Multivariate Cox proportional hazard regression models were used to compute hazard ratios (HRs) for the association between CAC progression and death.

Results: Overall, all-cause mortality was seen in 95 individuals (66%) during a mean follow-up of 7.9+-5.4 years (51% men, 63% diabetic). Just over 86% (126) ESRD subjects had CAC >0 at baseline. Subjects who died from any cause had significantly higher CAC and CAC progression. ESRD subjects with an annualized CAC progression score greater than 131 were associated with increased risk for all-cause mortality (hazard ratio [HR] 2.35; 95% confidence interval [CI] 1.42 - 3.89: p= 0.0008).

Conclusion: All-cause mortality was twice as likely in ESRD patients if their CAC score progression was >131/year.

